<DOC>
	<DOCNO>NCT01520363</DOCNO>
	<brief_summary>Dr. Sakkubai Naidu , Principal Investigator , initiate double blind placebo control clinical drug trial use dextromethorphan ( DM ) Rett Syndrome ( RTT ) , Pediatric Clinical Research Unit ( PCRU ) Johns Hopkins Hospital/Kennedy Krieger Institute . Funding Source- FDA OOPD Johns Hopkins Institute Clinical Translational Research ( ICTR ) . It show receptor certain brain chemical call glutamate , particular NMDA type , increase brain young RTT patient ( &lt; 10 year age ) . This chemical receptor , excess , cause harmful over-stimulation nerve cell brain , contribute part seizure , behavioral problem , learn disability RTT . The investigator propose initiate specific treatment use DM counter/block effect brain chemical excessive receptor improve ill effect increase glutamate/NMDA receptor , DM 's identified ability block NMDA receptor . DM available human consumption . Infants child respiratory infection cough , well non-ketotic hyperglycinemia , treat DM , well tolerate .</brief_summary>
	<brief_title>Placebo Controlled Trial Dextromethorphan Rett Syndrome</brief_title>
	<detailed_description>The study last 3 month limit MECP2 mutation-positive child , one year - 9.99 year age . This clinical trial , placebo-controlled study , randomize patient drug placebo determine benefit DM v placebo cognition , behavior , seizures present . Your child stay twice Pediatric Clinical Research Unit ( PCRU ) Johns Hopkins ICTR , 3 day admission . The first hospital stay 3 day , start DM placebo . The follow-up 3-day hospital stay 3 month start take DM placebo . There also two interim follow evaluation 2 week 1 month start take DM placebo consist neurological evaluation , EKG , blood work , take place local doctor 's office Johns Hopkins , pay study . Our research nurse research associate contact least weekly first month , least monthly thereafter end 3-month study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>male female classic atypical RTT proven mutation MECP2 gene ; subject must one year 10 year age . without establish mutation MECP2 gene ; mutation MECP2 gene brain resection surgical intervention ; example , tumor , hydrocephalus , severe head trauma ; , associate severe medical illness vasculopathies , malignancy , diabetes , thyroid dysfunction , etc ; medication could interact DM , e.g . MAO inhibitor , SSRI , sibutramine etc . avoid serotonin syndrome ; quinidine drug metabolize CYP450 isoform CYP2D6 ( e.g . amiodarone , haloperidol , propafenone , thioridazine ) ; prove intermediate slow metabolizers DM ; report adverse reaction DM ; whose pregnancy test positive ; show poor compliance aspect study ; foster child .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Rett syndrome</keyword>
	<keyword>RTT</keyword>
	<keyword>MECP2</keyword>
	<keyword>dextromethorphan</keyword>
	<keyword>DM</keyword>
</DOC>